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Abstract: The contribution of recently established or candidate susceptibility genes to melanoma
missing heritability has yet to be determined. Multigene panel testing could increase diagnostic yield
and better define the role of candidate genes. We characterized 273 CDKN2A/ARF and CDK4-negative
probands through a custom-designed targeted gene panel that included CDKN2A/ARF, CDK4, ACD,
BAP1, MITF, POT1, TERF2IP, ATM, and PALB2. Co-segregation, loss of heterozygosity (LOH)/protein
expression analysis, and splicing characterization were performed to improve variant classification.
We identified 16 (5.9%) pathogenic and likely pathogenic variants in established high/medium
penetrance cutaneous melanoma susceptibility genes (BAP1, POT1, ACD, MITF, and TERF2IP),
including two novel variants in BAP1 and 4 in POT1. We also found four deleterious and five likely
deleterious variants in ATM (3.3%). Thus, including potentially deleterious variants in ATM increased
the diagnostic yield to about 9%. Inclusion of rare variants of uncertain significance would increase
the overall detection yield to 14%. At least 10% of melanoma missing heritability may be explained
through panel testing in our population. To our knowledge, this is the highest frequency of putative
ATM deleterious variants reported in melanoma families, suggesting a possible role in melanoma
susceptibility, which needs further investigation.
Keywords: familial melanoma; genetic susceptibility; gene panel sequencing; high-penetrance genes;
variant interpretation; missing heritability; CDKN2A; ATM; BAP1; POT1
1. Introduction
Phenotypic and environmental factors, such as skin phototype, presence of atypical nevi, exposure
to sunlight, and sunburn, are known to increase the risk of cutaneous melanoma (CM). However, 5% to
12% of CM cases have a positive family history for this malignancy. Until a few years ago, CDKN2A/ARF
(cyclin dependent kinase inhibitor 2A) and its binding partner CDK4 (cyclin dependent kinase 4)
were the only known melanoma-predisposition genes tested in clinical practice. Germline pathogenic
variants in CDKN2A/ARF have been found in 20–45% of familial CM cases [1] and in 11–19% of multiple
primary melanomas (MPM) [2] from the Italian population, characterized by a high prevalence of
CDKN2A pathogenetic variants [3] often associated with pancreatic cancer (PC) and other cancers [4,5].
Conversely, a small number of families carrying pathogenic variants in CDK4 have been described
worldwide, including some Italian families [6,7].
As cancer predisposition syndromes and their associated genes are being clarified, previously
unappreciated overlaps are being identified. Indeed, some CM genes are associated with different
cancer types, and genes with known predisposition to other cancers may also increase the risk of
CM. Several distinct CM syndromes have been defined and genetic tests are now available for the
associated causative genes [8].
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Recently, novel rare high-risk variants have been identified in BAP1 (BRCA1 associated protein 1),
POT1 (protection of telomeres 1), ACD (adrenocortical dysplasia), TERF2IP (telomeric repeat-binding
factor-2 interacting protein), and the TERT (telomerase reverse transcriptase) promoter primarily
by whole exome sequencing (WES) studies, although differences in terms of prevalence have been
reported across studies [1,9–13]. TERT promoter variants have been reported in just two families [14,15].
Moreover, MITF (melanocyte inducing transcription factor) has emerged as an intermediate penetrance
risk gene for CM. Namely, carriers of the MITF p.Glu318Lys variant have a greater than fivefold
increased risk of developing melanoma, especially MPM, with specific dermatological and dermoscopic
features and with renal cell carcinoma (RCC) or both compared with non-carriers [16–21]. On the basis
of this evidence, it has been proposed that the aforementioned genes should be added to CDKN2A and
CDK4 in gene panels for routine diagnostic testing [8,22].
Familial clustering of additional cancer types, such as CDKN2A-associated PC and
p14arf-associated nervous system tumors, has long been described in CM families [23–26]. Further,
in families with pathogenic variants in novel susceptibility genes, CM is part of a broader multi-cancer
syndrome [8,27]. In addition to CM, the tumor spectrum of BAP1 pathogenic variants includes
uveal melanoma (UM), mesothelioma, basal cell carcinoma (BCC), renal cell carcinoma (RCC),
and BAP1-inactivated melanocytic tumors (BIMTs), which together constitute the BAP1-tumor
predisposition syndrome (BAP1-TPDS) [27]. Moreover, POT1 pathogenic variants predispose to
glioma, thyroid cancer, cardiac angiosarcoma, and colorectal cancer [28–31]. Lastly, ACD and TERF2IP,
as well as TERT promoter variants, are associated not only with early onset and multiple CM, but also
with other cancers, although these latter associations are not yet conclusively defined [12].
Pathogenic variants in the above-mentioned genes appear to be extremely rare in the context of
non-syndromic familial aggregation (i.e., a familial clustering of only one type of cancer, such as CM).
Conversely, recent exome sequencing studies on PC-only families identified pathogenic variants in the
ATM (ataxia-telangiectasia mutated) [32,33] and PALB2 (partner and localizer of BRCA2) genes [34,35].
ATM is a known intermediate penetrance cancer predisposition gene, as heterozygous carriers of
ATM germline pathogenic variants are at increased risk of developing several types of malignancies [36],
including breast cancer (BC) and PC. The findings of genome-wide association studies (GWASs) suggest
that ATM may be a low-risk melanoma susceptibility locus [37,38], but functional alleles have not yet
been identified. In a recent WES study on PC cases from CDKN2A-positive and negative CM families,
ATM loss-of-function (LOF) variants were mostly observed in CDKN2A-negative PC patients [39].
In another WES study, a potentially deleterious missense variant in ATM detected in a CM family
co-segregated with CM in three affected members whose mother developed PC [26].
Most ATM variants are, however, of uncertain significance, and the role of ATM in CM
predisposition has yet to be clarified.
In addition, low penetrance genes such as MC1R (melanocortin 1 receptor) and far more than
20 other low penetrance risk loci have recently been associated with CM through Sanger sequencing
(SS) and WES studies, as well as GWAS [37,40].
Although the individual alteration of each of these loci is likely not sufficient to drive oncogenesis,
the interplay of multiple low penetrance risk alleles may increase personal CM risk above a critical
threshold, leading to familial clustering of CM. The validation of a polygenic score is currently
underway to verify this hypothesis [41–43].
All these issues should be addressed during CM genetic risk assessment in both research and
clinical settings, to improve the efficiency of genetic referral, counselling, and testing.
For this study, we performed germline sequencing through a multigene panel that included
established and candidate predisposition genes, in a cohort of Italian CM patients deemed at high-risk
according to recent established criteria [8], but negative for CDKN2A/ARF and CDK4 pathogenic
variants. Our aims as follows: to validate, in CM cases with a high risk of genetic susceptibility,
a comprehensive gene panel containing all established CM susceptibility genes identified so far,
and a few novel candidates; to assess the frequency of pathogenic variants; and to evaluate the potential
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impact of this panel in the clinical practice in terms of increased diagnostic yield and of interpretational
challenges of novel variants. Under the hypothesis that part of the aggregation of PC seen in our CM
families could be ascribed to variants in ATM and PALB2, we decided to include these genes in our
panel, with the purpose of investigating their potential role in CM predisposition.
2. Results
2.1. Panel Validation
To determine the sensitivity and specificity of our next-generation sequencing (NGS) platform
and bioinformatics algorithm, we first sequenced 10 DNA samples with known CDKN2A/ARF, CDK4,
and MC1R germline variants previously found through SS. The NGS results were fully concordant
with the previous SS results. All samples from the patients included in the study, previously
sequenced for CDKN2A/ARF and CDK4, were confirmed to be negative by NGS. A 100% concordance
in single-nucleotide polymorphisms (SNPs) detection in CDKN2A/ARF and MC1R was observed.
2.2. Detection Yield and Variant Interpretation in Established and Candidate Melanoma Predisposition Genes
Out of 273 probands who underwent gene panel testing, we identified 16 (5.9%) pathogenetic or
likely pathogenic variants in established high/intermediate penetrance CM susceptibility genes such as
BAP1 (2.2%; n = 6), POT1 (0.7%; n = 2), ACD (0.37%; n = 1), and MITF (2.6%; n = 7). We also found
eight variants of uncertain significance (VUS): one in BAP1, six in POT1, and one in TERF2IP.
In addition, we found four deleterious variants and five potentially deleterious variants (3.3%) as
well as six rare VUS in ATM, whereas no rare variants were found in PALB2. The detection yield of each
gene, considering deleterious and potentially deleterious variants, with or without VUS, respectively,
is reported in the titles of the following gene-specific paragraphs (for pedigrees, see Figure S1).
2.2.1. BAP1 (2.2–2.5%)
Overall, we identified six variants, five frameshift and one non-sense, which were classified
as pathogenic, as well as one VUS in the BAP1 gene. Of these, two frameshift variants were novel,
whereas we had already reported the remaining variants in the meta-analysis by Walpole et al. [44],
but none of them were found in our control cohort. All families with LOF variants showed the typical
features of the BAP1-TPDS (OMIM 614327) as well as multiple cases of CM (Table 1).
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Table 1. Rare variants in melanoma high penetrance genes ACD, BAP1, POT1, and TERF2IP and in medium penetrance gene MITF.
Case Index (Age of
Diagnosis) Gene
1 Description and
Consequence Type
ACMG
Classification 2 DbSNP
3 gnomAD 4 CADD 5 SIFT 6 Polyphen 7 LRT 8
Mutation
Taster
Other Cancer in
Family Clin Var
9 Co-Segregation 10
Total No. of cm/um
Cases in Family
MPM (58) ACD c.866_867delCT;p.(Pro289ArgfsTer28) frameshift LP rs777476880 2.44e-05 - - - - - BC, LC, PC - ND 3 CM
CM (31) BAP1 c.327_328insGA;p.(Pro110AspfsTer4) frameshift P - - - - - - - 2 MES - ND 1 CM
UM (45), RCC (40) BAP1 c.639dupT;p.(lIe214TyrfsTer29) frameshift P - - - - - - - 2 KC, 2 UM Y 3 UM
CM (53), MES (55) BAP1 c.799_800delCA;p.(Gln267AlafsTer16) frameshift P - - - - - - - 3 CM, LC, 2 MES Y 4 cCM
MPM (41, 43) BAP1 c.1337delA;p.(Asn446ThrfsTer125) frameshift P - - - - - - - UM, BC ND 1 UM, 3 CM
CM (52) BAP1 c.1507T>C;p.(Phe503Leu) missense VUS rs745959970 3.99e-06 23.6 D D D D CM ND 2 CM
AST (23) BAP1 c.1777dupC;p.(Gln593ProfsTer50) frameshift P - - - - - - RCC - ND 1 AST
AST (35), AGM BAP1 c.1939G>T;p.(Glu647Ter) non-sense P - - - - - - BC, BCC, UM Y 1 AST, 1 UM
CM (26) POT1 c.158C>T;p.(Thr53Ile) missense VUS - - 21.3 D D D D 3 CM, GLB, PC, HL - Y 4 CM, 1 UM
MPM (66, 66) POT1 c.158C>T; p.(Thr53Ile) missense VUS - - 21.3 D D D D CM - Y 3 CM
MPM (39, 39, 40) POT1 c.255+1G>A splicing P - - - - - - - CM, BC, CC, LC, L - ND 4 CM
CM (45), OC (23), MES (50) POT1 c.280C>A; p.(Gln94Lys) missense VUS - - 22.8 D D D D LC - ND 1 CM
MPM (46, 52) POT1 c.314C>T;p.(Thr105Met) missense VUS - - 28.8 D D D D AST, BC, LC - ND 2 CM
MPM (40), GL, MY POT1 c.809G>A;p.(Ser270Asn) missense VUS rs587777477 - 23.2 D B D D LC, S RF ND 9 CM
MPM (40, 52) POT1 c.1400C>T;p.(Ser467Leu) missense VUS rs1410842025 - 17.52 D PD N D CM, GLB - ND 3 CM
CM (17) POT1 c.1687-1G>A splicing P rs587777473 4.28e-06 - - - - - CM, RCC RF Y 2 CM
MPM (40, 51) TERF2IP c.258C>G; (p.Asp86Glu) missense VUS rs752446617 6.14e-06 23.9 T B D D BLC, BCC - ND 2 CM
MPM (32) MITF c.952G>A; p.Glu318Lys missense LP rs149617956 1.36e-03 27.9 D P D D - UNC ND 10 CM
CM (23) MITF c.952G>A; p.Glu318Lys missense LP rs149617956 1.36e-03 27.9 D P D D CM UNC Y 2 CM
MPM (59) MITF c.952G>A; p.Glu318Lys missense LP rs149617956 1.36e-03 27.9 D P D D KD UNC ND 3 CM
CM (39), TC (38) MITF c.952G>A; p.Glu318Lys missense LP rs149617956 1.36e-03 27.9 D P D D UNC ND 1 CM
MPM (62, 62, 72) MITF c.952G>A; p.Glu318Lys missense LP rs149617956 1.36e-03 27.9 D P D D UNC ND 3 CM
MPM (45, 46) MITF c.952G>A; p.Glu318Lys missense LP rs149617956 1.36e-03 27.9 D P D D BC UNC ND 2 CM
MPM (52, 62, 65) MITF c.952G>A; p.Glu318Lys missense LP rs149617956 1.36e-03 27.9 D P D D CM UNC ND 4 CM
1 Gene reference: ACD LRG_1237 (NM_001082486.2); BAP1: LRG_529 (NM_004656.2); POT1 (NM_015450); TERF2IP: LRG_1084 (NM_018975.3); MITF: LRG_776 (NM_000248.3).
2 ACMG: American College of Medical Genetics and Genomics; 3 dbSNP: single nucleotide polymorphism database; 4 gnomAD: genome aggregation database; 5 CADD: combined
annotation-dependent depletion; 6 SIFT: sorting intolerant from tolerant; 7 PolyPhen: polymorphism phenotyping; 8 LRT: likelihood ratio test; 9 Clin Var (ClinVar aggregates information
about genomic variation and its relationship to human health); 10 co-segregation analysis of variant with melanoma phenotype in the family (Y: the observed variant co-segregates in at
least two affected members; ND: not done). Abbreviations: ACD: adrenocortical dysplasia; BAP1: BRCA1 associated protein 1; POT1: protection of telomeres 1; TERF2IP: telomeric
repeat-binding factor-2 interacting protein; MITF: melanocyte inducing transcription factor; BC: breast cancer; BCC: basal cell carcinoma; BLC: bladder cancer; CC: colon cancer;
CM: cutaneous melanoma; D: deleterious; GC: gastric cancer; HL: Hodgkin lymphoma; LX: larinx cancer; LP: likely pathogenic; MES: malignant mesothelioma; MPM: multiple primary
melanoma; ON: oncocytoma; P: pathogenic; PC: pancreatic cancer; PR: prostate cancer; T: tolerant; UC: uterine cancer; UM: uveal melanoma; UNC: uncertain; VUS: variant of unknown
significance. The variants in bold are novel.
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The patient with the novel c.1337delA variant developed a spitzoid CM at the age of 41, as well as
a further CM and two dysplastic nevi—one classified as spitzoid—at the age of 43. Her father had died
of UM at the age of 51.
The second novel variant, c.1777dupC, which is predicted to cause a truncated protein after
50 amino acids, was found in a young patient diagnosed with an atypical Spitz nevus/tumor with loss
of BAP1 expression and with a second-degree relative deceased owing to RCC at the age of 46.
The patient with c.799_800delCA developed CM and had a brother previously diagnosed with
three CMs and a mesothelioma. One year after BAP1 genotyping, mutation-specific follow-up allowed
an early diagnosis of mesothelioma in the proband. We tried to assess loss of heterozygosity (LOH) by
tumor DNA sequencing in both melanomas and mesothelioma tissue; unfortunately, low DNA quality
limited our analysis, but immunohistochemistry (IHC) showed loss of BAP1 nuclear expression in the
mesothelioma sample (see Figure S2).
Additionally, in a patient diagnosed with CM at the age of 52, we identified a missense BAP1
variant, c.1507T>C p.(Phe503Leu), which was found in The Genome Aggregation Database (gnomAD)
with a very low frequency in the non-Finnish European population (f = 3.99e-6).
The patient’s sister developed CM at the age of 23, but segregation in the family could not be
verified as BAP1 germline status was only available for the proband, the family history was not
suggestive for a BAP1 mutation, and the variant was thus classified as VUS.
2.2.2. POT1 (0.7–2.9%)
Multiple variants in the POT1 gene (four of them novel) were identified, including two pathogenic
splicing variants and six missense VUS.
The c.255+1G>A novel variant, involving the same canonical splice site of a variant functionally
described by Potrony et al. [45], was found in a patient who developed three CMs and several dysplastic
nevi, as well as in his unaffected mother and sister. cDNA analysis confirmed the resulting previously
described exon 7 skipping, which was overrepresented in carriers compared with non-carriers
(approximately 50% vs. 10%) (Figure 1).
The c.1687-1G>A variant, which was predicted to be pathogenic by the MaxEntScan algorithm,
and was previously shown to affect transcript splicing by RT-PCR and sequencing by Robles-Espinoza
et al. [10], was found in a family with two CM cases and an RCC case.
Three of the six POT1 missense variants (c.158C>T, c.280C>A, and c.314C>T) were located in the
DNA binding domain (OB1). c.158C>T p.(Thr53Ile), predicted to be pathogenic by in silico analysis,
was detected in two different CM families: one included individuals with glioblastoma and PC,
while the second was a CM-only family, with two affected CM members. In both families, the variant
co-segregated with CM. The c.280C>A p.(Gln94Lys) variant, which, according to A.J. Ramsay et al. [46],
may disrupt electrostatic interactions with telomeric DNA, was identified in a patient diagnosed with
CM at the age of 45, ovarian neoplasm at the age of 23 and papillary peritoneal mesothelioma at the
age of 50. The third variant, c.314C>T p.(Thr105Met), is phylogenetically highly conserved (suggesting
that this threonine has an essential role in protein function) and was found in a MPM proband who
also developed a dysplastic nevus and whose nephew had an atypical Spitz lesion.
Of the remaining missense variants, c.809G>A p.(Ser270Asn) was found in a patient with more
than 50 melanocytic nevi who developed nine CMs and was diagnosed with multiple myeloma at
the age of 54. After bone marrow transplantation, the patient developed an oligodendroglioma and a
mixosarcoma. Moreover, his mother developed a spinal cord tumor at the age of 65.
The last missense variant, c.1400C> p.(Ser467Leu), was found in a patient who developed two
CMs and whose mother developed a CM at the age of 50 and a glioblastoma at the age of 79.
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Schematic representation of the splicing of exon 7 (113bp) owing to the c.255 + 1G>A variant. (b) 
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Figure 1. Pedigree with the POT1 c.255+1G>A variant and the resulting splicing of exon 7. (a) Schematic
representation of the splicing of exon 7 (113bp) owing to the c.255+1G>A variant. (b) Electrophoresis of
the cDNA from the four family members, including three (the affected proband, sister, and mother) who
carry the variant c.255+1G>A; the father from the unaffected branch of the family who does not carry
the variant; and two healthy controls (CTRL-), showing two different transcripts, the shortest resulting
from the skipping of exon 7, and overrepresented in carriers compared with non-carriers. (c) cDNA
sequencing confirmed that the mutant allele produced the shorter isoform, with skipping of exon 7,
in a higher proportion of the transcript in carriers vs. non-carriers. The blue arrow indicates the lower
relative abundance of the spliced isoform (ex 6–8) in noncarriers vs. carriers (red arrow). (d) Pedigree
diagram of the family carrying the c.255+1G>A variant. Dark symbol: cutaneous melanoma (CM).
Cancer type and age at diagnosis are indicated under each symbol. The proband is indicated by
an arrow. +: carrier, −: non-carrier.
2.2.3. ACD (0.36%), TERF2IP (0.36%), and TERT (0%)
We found the c.866_867delCT frameshift variant in ACD that leads to a premature truncating
protein in a patient affected by multiple CM and with a family history of CM and a relative who died
of PC at the age of 55. Additionally, an MPM patient, with no family history of CM, had a VUS in the
TERF2IP gene, c.258C>G p.(Asp86Glu).
None of the 273 probands carried the c.-57T>G or other germline pathogenic TERT
promoter variants.
2.2.4. MITF (2.6%)
The MITF c.952G>A p.(Glu318Lys) risk variant was detected in 7 out 273 probands, four of whom
had a history of MPMs and dysplastic nevi, one was also affected by RCC, and another who had a
second degree relative also diagnosed with CM.
2.2.5. PC-Associated Candidate Genes: ATM (3.3–5.5%) and PALB2
Nine potentially pathogenic (four deleterious and five potentially deleterious variants) and six
VUS were found in ATM. c.3275C>A p.(Ser1092Ter) was detected in a CM proband with a second
degree relative affected by PC. Three frameshift variants, predicted to cause truncated proteins owing
to premature stop codons, were detected in families with MPM, UM, and other cancers (Table 2).
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Table 2. Rare variants of interest in ATM candidate gene.
Case Index
(Age of
Diagnosis)
Gene 1 Description and Consequence Type
ACMG
Classification 2 DbSNP
3 gnomAD 4 CADD 5 SIFT 6 Polyphen 7 LRT 8
Mutation
Taster
Other
Cancer in
Family
Clin Var 9 Co-Segregation 10
Total No.
of cm/um
Cases in
Family
CM (24) ATM c.1516G>T:p.(Gly506Cys) missense VUS rs587779816 29.0 D P D D ON, PC UNC ND 1 CM
CM (48) ATM c.1595G>A:p.(Cys532Tyr) missense VUS rs35963548 21.0 D D D D 2 CM, BC UNC ND 3 CM
CM (47) ATM c.3275C>A;p.(Ser1092Ter) nonsense P - - - - - D D PC, LC - ND 1 CM
MPM (42, 42) ATM c.3576G>A;p.(Ser1135_Lys1195del58) splicing LP rs587776551 1.63e-05 - - - - - CM P ND 3 CM
CM (49) ATM c.3576G>A;p.(Ser1135_Lys1195del58) splicing LP rs587776551 1.63e-05 - - - - - CM, UC P ND 2 CM
MPM (40, 40) ATM c.3576G>A;p.(Ser1135_Lys1195del58) splicing LP rs587776551 1.63e-05 - - - - - MPM, BCC,PC, PR P Y 4 CM
MPM (35, 63) ATM c.3934A>G:p.(Arg1312Gly) missense VUS rs864622137 23.3 D D D D LC, BR, GC UNC ND 2 CM
CM (45) ATM c.4049C>T:p.(Thr1350Met) missense VUS rs587781785 27.0 T D D D CM UNC ND 3 CM
CM (50) ATM c.4306C>T:p.(His1436Tyr) missense VUS rs544891616 17.09 T D D D 2 KD UNC ND 1 CM
HL (35),
MPM (45, 45,
46), BCC (49),
PC (50)
ATM c.4451delT:p.(Met1484ArgfsTer15) frameshift P - - - - - - CM, CC,LC, PC - ND 4 CM
CM (47) ATM c.5750G>C:p.(Arg1917Thr) missense LP rs377289524 1.22e-05 25.6 T D D D
CM, UM,
BC, BLC,
PR, CC, GC
UNC Y 2 CM,1 UM
MPM (45, 46) ATM c.5750G>C:p.(Arg1917Thr) missense LP rs377289524 1.22e-05 25.6 T D D D PR UNC ND 2 CM
2 UM (41),
CM (51) ATM
c.5979_5983delTAAAG;
p.(Ser1993ArgfsTer23) frameshift P rs876660134 8.13e-06 - - - - - BC, GC, LX P ND
1 CM,
2 UM
MPM (48, 48,
53), BCC (49) ATM
c.8319_8323dupTGTCC;
p.(Pro2775LeufsTer33) frameshift P rs1060501552 - - - - -
MPM, BCC,
PC, PR P ND 5 CM
CM (43) ATM c.8557A>G:p.(Thr2853Ala) missense VUS - 27.7 D D D D MES UNC ND 1 CM
1 Gene reference: ATM LRG_135 (NM_000051.3). 2 ACMG: American College of Medical Genetics and Genomics; 3 dbSNP: single nucleotide polymorphism database; 4 gnomAD: genome
aggregation database; 5 CADD: combined annotation-dependent depletion; 6 SIFT: sorting intolerant from tolerant; 7 PolyPhen: polymorphism phenotyping; 8 LRT: likelihood ratio test;
9 Clin Var (ClinVar aggregates information about genomic variation and its relationship to human health); 10 co-segregation analysis of variant with melanoma phenotype in the family
(Y: the observed variant co-segregates in at least two affected members; ND: not done). Abbreviations; ATM: ataxia-telangiectasia mutated; BC: breast cancer; BCC: basal cell carcinoma;
BLC: bladder cancer; CC: colon cancer; CM: cutaneous melanoma; D: deleterious; GC: gastric cancer; HL: Hodgkin lymphoma; LX: larinx cancer; LP: likely pathogenic; MES: malignant
mesothelioma; MPM: multiple primary melanoma; ON: pncocytoma; P: pathogenic; PC: pancreatic cancer; PR: prostate cancer; T: tolerant; UC: uterine cancer; UM: uveal melanoma;
UNC: uncertain; VUS: variant of unknown significance. The variants in bold are novel.
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Of these, c.4451delT was found in a proband who was treated 10 years earlier with cyclosporine
and radiotherapy for a Hodgkin’s lymphoma, and subsequently developed three CMs, two at the
age of 45 and one at age 46. The proband also reported a cousin diagnosed with CM who died
at the age of 33, while his mother developed a colon adenocarcinoma at age 71 and PC at age 74.
A cousin of the mother developed PC at the age of 76. In consideration of personal and family history,
the presence of the ATM variant was reported to the proband in a research context, with emphasis on the
uncertainty about the role of ATM in melanoma and PC development and the absence of a standardized
surveillance protocol. As the patient was under active follow-up for his prior diseases, a specific
PC surveillance was not recommended. Recently, almost three years later, the routine follow-up
allowed diagnosis of PC for this patient. The diagnosis was confounded by an acute pancreatitis and
uncertainty at computed tomography (CT) and positron emission tomography (PET) scans followed
by cholangio-nuclear magnetic risonance (NMR). Shortly after histologic diagnosis was confirmed at
ultrasound (US) endoscopy, the disease rapidly evolved with hepatic metastastases.
c.5979_5983delTAAAG, which causes a premature stop codon after 23 aa, was found in a proband
who developed two Ums at the age of 41 and a CM 10 years later.
The last frameshift variant, c.8319_8323dupTGTCC, was found in a woman who developed two
CMs at the ages of 48 and one at 53, as well one BCC and a BC (at the ages of 49 and 53, respectively).
The c.3576G>A p.(Ser1135_Lys1195del58) variant, a splicing mutation resulting in the skipping of
the entire exon 24 of the ATM gene [47], was found in three probands belonging to CM families, two of
whom developed MPM and have a first degree relative affected by CM.
The c.5750G>C p.(Arg1917Thr) missense variant was found in two probands. The first one, a CM
patient diagnosed at the age of 47, belonged to a family in which the variant co-segregated with the
sister (CM at the age of 43) and their father developed prostate, bladder, colon cancer, and UM (at the
ages of 70, 71, 72, and 74, respectively).
The second proband harboring the p.(Arg1917Thr) variant was an apparently sporadic MPM
patient, with no other tumor in the family. This patient was also a carrier of aMITFp.(Glu318Lys) variant.
More details on family histories are available in Figure S1.
In addition to the above-mentioned variants, we found six additional missense variants, all of
uncertain significance (Table 2). Conversely, no rare variants were found in the PALB2 gene.
2.2.6. CDKN2A/ARF and CDK4
We did not find previously undetected pathogenic variants in CDK4 and CDKN2A/ARF,
although we included regulatory regions, for example, the whole CDKN2A/ARF 5′UTR, as we recently
showed that nearly half of the rare 5′UTR germline variants are potentially pathogenic, owing to their
impact on CDKN2A/ARF internal ribosome entry site (IRES)-mediated translation [48,49].
3. Discussion
The overall contribution of recently identified CM predisposition genes (ACD, BAP1, POT1, MITF,
and TERF2IP) to melanoma’s missing heritability is estimated to be about 2% [22]. Initial findings of
pathogenic variants in POT1, however, considered the second most frequently mutated high penetrance
gene after CDKN2A/ARF, showed a higher frequency, probably owing to the presence of founders in the
studied populations [8,10]. Therefore, these reports need to be confirmed by further studies. Currently,
pathogenic variants in recently identified CM predisposition genes are detected at a frequency similar
to that of pathogenic CDK4 variants, which was routinely screened in familial and MPM patients
together with CDKN2A/ARF. These data supported the inclusion of these genes in clinical genetic
testing panels [8,22,50,51]. With this study, we evaluated the efficiency and the potential clinical benefit
of a customized multi-gene panel for CM risk that could enhance genetic testing offered to Italian
CM families and MPM patients. In addition to the whole CDKN2A/ARF gene (including the 5′UTR),
and exon 2 of CDK4, this panel included the novel established high penetrance genes, that is, ACD,
BAP1, POT1, TERF2IP, as well as the intermediate penetrance gene MITF. TERT promoter was analyzed
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by SS. We also included ATM and PALB2 for research purposes, excluding them from the clinical report,
under the assumption that their variants could play a role in families with known cancer associations,
that is, CM and PC [26,39,52,53].
Overall, the detection yield of pathogenic/likely pathogenic variants in established melanoma
risk genes was 5.86%. When deleterious and potentially deleterious ATM variants were also included,
the detection yield rose to 9.16%, the highest estimate described so far to our knowledge.
However, the association between variants in ATM, mostly known for being associated with a
low-intermediate risk of other cancers, and CM risk is not yet clearly established.
Indeed, our study may provide useful information to help tackle those issues hampering the
implementation of research discoveries in clinical practice. An increase in the detection yield needs
to be integrated with a thorough evaluation of the pathogenicity of variants, especially novel ones,
because of the potential clinical impact. Any VUS is subject to future reassessments of clinical
impact. Further, the detection of a pathogenic variant in a gene such as BAP1, which is related to
a complex syndrome that includes several potentially lethal cancers, should be reported to aid clinical
management, even though the complete tumor spectrum and related tumor-specific penetrance and
surveillance recommendations are not definitively drawn.
In our cohort, the overall detection rate of LOF in BAP1 was 2%. However, if we restricted
assessment to patients/families meeting criteria [8] for the BAP1 syndrome (n = 36), our detection
rate rose to 16.7%. For an appropriate clinical management of BAP1-TPDS patients, we suggested
a surveillance plan based on preliminary proposals [27], informing the patients about the risk of
additional cancers associated with the syndrome and about the uncertainty of the efficacy of surveillance
for some of these cancers.
For patients with MITF p.(Glu318Lys), based on the association of a higher risk of MPM, dysplastic
nevi, and RCC, and on the basis of our data [18], we propose the inclusion of this gene in clinical
diagnostic testing and suggest that an annual abdominal ultrasound should be integrated with the
dermatological surveillance for the carriers, even though tailored surveillance for cancers other than
CM is not standardized [51].
Specific recommendations are not yet available for multiple variants/genes such as POT1 variants.
Therefore, the impact on surveillance of these novel melanoma risk genes should be considered and
communicated, bearing in mind that they will not be definitive until a consensus is reached based on
the results of international multicentric studies, such as those conducted by the BIG consortium (BAP1
interest group, http://www.bap1.org) for the BAP1 gene.
Interestingly, our study cohort showed a higher rate of ATM variants than that reported in recent
WES and WGS studies that included melanoma [54,55]. One reason could be that those studies were
performed on melanoma patients, regardless of family history, whereas our cohort included high-risk
individuals, more likely to carry germline risk alleles. However, these data are not enough to assess
whether ATM is involved in melanoma predisposition.
The finding of ATM LOF variants in our study cohort is in line with previous findings on the
association between ATM and CM/PC risk [26,39]. In fact, four deleterious and five potentially
deleterious variants were found, three of them in melanoma-prone families that also included PC
cases. Co-segregation in PC cases, however, could not be determined. Therefore, PC occurrence in
these families may only partially explain this high detection rate, although one ATM positive patient
developed both melanoma and PC. Therefore, further studies are needed to determine whether ATM
is a risk factor for melanoma.
Moreover, surveillance for other cancers for which ATM is a medium penetrance predisposition
gene (for instance, BC) is still under debate and discussion [53,56–58].
Overall, the search for variants in recently identified genes consistently associated with risk of
CM is a step forward to improve diagnostic genetic-testing panels and to evaluate differences in
geographical distribution. Recently, Potjer et al. [59] found no variants in POT1, and occurrence of
UM and mesothelioma in three BAP1 positive families in a large multigene panel study of 451 Dutch
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families with an overall diagnostic yield of 4%, principally explained by the identification of 15 MITF
positive families (3.3%). Casula et al., in a cohort of Italian MPM patients, used a panel containing
the same genes we tested (with the exception of MITF), and found a lower pathogenic variant rate,
considering the American College of Medical Genetics on Genomics (ACMG) variant classification
(3%) [60]. CDKN2A pathogenic variants were also less frequent (3.84%) [2,3]. More work is needed to
evaluate different diagnostic panels, within and across geographic areas.
This study naturally has some limitations. We were limited in our ability to verify co-segregation
in most families because affected family members were deceased or not available, resulting in some
variants being classified as VUS. Unfortunately, this is a common issue in the diagnostic setting.
In addition, we recognize the importance of functional analysis and agree that segregation analysis
coupled with functional assays is currently the best approach to classify gene variants. Functional
validation will be part of future studies that will help define the role of these variants/genes in melanoma
susceptibility. Another minor limitation is that the panel did not include several rare/very rare recently
proposed candidate melanoma genes such as GOLM1 (golgi membrane protein 1) [61], POLE (DNA
polymerase epsilon, [62]), NEK11 [63], EBF3, OCA2, TYR, TYRP1, and SLC45A2 [26,59,64–66], reviewed
in [67].
4. Materials and Methods
4.1. Study Cohort
We selected 273 index cases, consecutively enrolled at our center for genetic testing and tested
negative for CDKN2A and CDK4. The genetic testing assessment is based on a clinical score that
incorporates criteria previously proposed for genetic testing for CM susceptibility [8], accounting for the
differences among areas with high or low incidence. It applies criteria to proceed with genetic testing
for cancers other than melanoma in families with members affected by CM: 167 probands belonged to
families with two or more affected CM members, 84 were apparently sporadic MPM patients, and 22
were apparently non-familial CMM or atypical Spitz nevus cases whose first/second degree relatives
were diagnosed with BAP1-TPDS related cancer or PC. When a pathogenic, likely pathogenic, or VUS
variant was identified, co-segregation analysis was performed, extending the analysis to other affected
family members, when available, for a total of 293 individuals tested. All patients were interviewed by a
medical geneticist in the context of clinical genetic counselling, using a standardized questionnaire that
comprised both family history and environmental exposures. In addition, 80 cancer-free controls from
the general population were selected, tested, and administered the same questionnaire. All subjects
enrolled in this study signed an informed consent for genetic testing and genetic-based research under
local Institutional Review Board (IRB) approved protocols (CE AOU San Martino Genova 10/2010).
4.2. Panel Design
We performed custom targeted sequencing covering coding exons and splice junctions of
CDKN2A/ARF (including exon 1 Beta and 5′UTR and promoter of exon 1alpha upstream to 400 bp
from ATG) [68], CDK4 exon2, ACD, BAP1, MITF exon 10, POT1, TERF2IP, ATM, and PALB2. Our panel
covered 98% of the regions targeted. The remaining 2% of uncovered regions were analyzed through
direct sequencing. TERT promoter sequence was excluded from the panel design owing to low
coverage and was instead analyzed through direct sequencing for all cases. The panel contained
198 amplicons for a total size of 55.5 Kb.
4.3. Targeted Sequencing and Variant Selection and Interpretation
In brief, libraries were prepared using the Ion Chef System, and then pooled and loaded into
PGM or S5 next-generation sequencing systems (Thermo Fisher Scientific, Waltham, MA, USA) for
automated sequencing. Ion sequencing data were analyzed using the Torrent Variant Caller software
within the Torrent Suite. Annotation was performed by uploading BAM files into Ion Reporter 5.10
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and wAnnovar [69], and both tools were used to annotate genetic variants. Only single nucleotide
variants and small indels covered for more than 20 reads were filtered in. Sequencing data were
filtered by frequency, in order to isolate clinically relevant mutations only in high/medium risk genes.
Variants were classified as pathogenic, likely pathogenic, VUS, likely benign, or benign based on the
published ACMG recommendations [70], for known melanoma genes. For ATM, however, we used
the term deleterious because the gene is not considered an established melanoma predisposition gene,
or a gene definitively known to cause the disease. Variants were named according to the Human
Genome Variation Society nomenclature (HGVS, https://varnomen.hgvs.org/). All identified putative
pathogenic variants and VUS were validated by SS.
4.4. Next-Generation Sequencing (NGS) Analysis
We filtered out common variants based on their frequency (MAF higher than 0.01) in the gnomAD
(Genome Aggregation Database https://gnomad.broadinstitute.org/) public database or in our cohort
of 80 healthy controls sequenced with the same panel. An additional filtering of non-synonymous
variants was performed according to the following tools: SIFT (sorting intolerant form tolerant,
Polyphen 2, LRT (likelihood ratio test), mutation taster, CADD (combined annotation-dependent
depletion) score > 15, and ClinVar. Synonymous variants were analyzed using Human Splicing Finder
(http://www.umd.be/HSF3/) and those without a predicted effect on splicing were excluded. Frameshift,
splicing, and stop-gain variants were defined as LOF.
4.5. BAP1 LOH/Protein Expression by Immunohistochemistry (IHC)
BAP1 LOH/protein expression by IHC was performed to verify BAP1 loss/inactivation using
a mouse monoclonal antibody raised against amino acids 430–729 of human BAP1 (C-4, Cat.
No. sc-28383; Santa Cruz, CA, USA) on Formalin-Fixed, Paraffin-Embedded (FFPE) mesothelioma
sections from patients included in the study cohort.
4.6. Splicing Analysis
To verify whether the variant c.255+1G>A alters splicing inPOT1, as described in Potrony et al. [45],
in which they tested the variant c.255G>A, we isolated total RNA from lymphoblastoid cells with
TRIzol (Invitrogen, Carlsbad, CA, USA) and cDNA synthesis was performed with the High-Capacity
cDNA Reverse Transcription Kit (Applied Biosystem, Foster City, CA, USA) using random primers.
PCR primers were designed to cover exons 6–9 of the POT1 gene and the same primers were used for
direct sequencing. The PCR products of the subjects carrying the variant and different controls were
loaded on an agarose gel. POT1 NM_015450 was used as a reference sequence.
5. Conclusions
Multigene panel sequencing, steadily becoming more affordable and accessible, has improved
cancer risk assessment in the clinical practice by allowing a more accurate identification and surveillance
of families at risk of CM. However, insights on the definition of novel cancer clusterings, or a complex
polygenic interplay that influences the clinical expression of a pathogenic variant, require larger
case-control studies to allow a finer personalization of cancer risk estimates. To the best of our
knowledge, this is the first study to report a high percentage of deleterious ATM variants in melanoma
families (3.3%). In fact, the finding of ATM deleterious or potentially deleterious variants in nearly 3.3%
of our families, and an additional 2.2% of rare VUS, has led to a multicenter international collaboration,
currently ongoing, to define the role of ATM as a susceptibility gene to CM. The fact that the risk for
some other types of cancer is not completely defined in CM families represents one of the challenges
arising from wide-range genetic testing, as well as a novel opportunity to identify potentially lethal
cancer-prone syndromes.
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genes; Figure S2: Pedigree diagram from the family with the rare c.799_800delCA BAP1 germline variant.
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